[10-Q] Core Laboratories Inc. /DE/ Quarterly Earnings Report

Rhea-AI Filing Summary

Core Laboratories (CLB) reported steady Q3 results. Revenue was $134.5 million, essentially flat year over year, while net income attributable to the company rose to $14.2 million, up 21%. Diluted EPS was $0.30 versus $0.25 a year ago. Services grew modestly to $101.1 million as international crude‑assay and diagnostics offset softer U.S. activity. Product sales declined to $33.4 million on weaker U.S. onshore completions.

Operating income improved to $20.9 million, aided by cost efficiencies and lower interest expense. Other income included a final insurance recovery gain of about $5.2 million related to the Aberdeen facility. Cash was $25.6 million; long‑term debt was $117.0 million gross. On July 22, the company entered a $150.0 million amended credit facility, with about $131.9 million of borrowing capacity available at quarter‑end. The board declared a $0.01 dividend on October 22, 2025. Year to date, CLB repurchased 831,478 shares for $9.8 million. After quarter‑end, CLB acquired Solintec in Brazil for an initial $2.3 million plus up to $3.7 million contingent, bolstering Reservoir Description.

Insights

Equity Research Analyst

Q3 EPS rose on stable revenue; mix shifts and one-time gain.

Core Laboratories posted Q3 revenue of $134.5M with net income of $14.2M. Services reached $101.1M as international assays and diagnostics supported growth; product sales were $33.4M amid softer U.S. onshore activity.

Profitability benefited from efficiencies and non-operating items. Other income included a final insurance recovery gain of about $5.2M, and interest expense fell. Management reported a leverage ratio of 1.10 and interest coverage of 7.86 for the period ended Sep 30, 2025, indicating covenant headroom under the $150.0M facility.

Capital returns remained measured: a $0.01 dividend declared on Oct 22, 2025 and YTD buybacks of 831,478 shares for $9.8M. The post‑quarter Solintec acquisition (initial $2.3M plus up to $3.7M earnout) adds regional capability to Reservoir Description. Actual impact will depend on execution and market activity.

false--12-310001958086Q3http://fasb.org/us-gaap/2025#FinanceLeaseLiabilityhttp://corelab.com/20250930#ChiefExecutiveOfficerAndChairmanOfBoardOfDirectorsMember0001958086us-gaap:OperatingSegmentsMemberus-gaap:CorporateAndOtherMember2025-07-012025-09-300001958086us-gaap:IntersegmentEliminationMemberus-gaap:CorporateAndOtherMember2025-07-012025-09-300001958086us-gaap:OperatingSegmentsMemberclb:OperatingSegmentReservoirDescriptionMember2025-09-300001958086clb:TwoThousandTwentyThreeSeniorNotesMemberus-gaap:SeriesBMember2024-12-310001958086us-gaap:TreasuryStockCommonMember2025-09-300001958086us-gaap:CommonStockMember2024-12-310001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:OperatingSegmentsMember2025-07-012025-09-300001958086currency:RUB2024-01-012024-09-300001958086us-gaap:CommonStockMember2024-09-300001958086us-gaap:LineOfCreditMembersrt:MinimumMember2025-09-300001958086us-gaap:IntersegmentEliminationMember2025-07-012025-09-3000019580862025-06-300001958086currency:CAD2025-07-012025-09-300001958086currency:COP2025-01-012025-09-300001958086currency:EUR2025-01-012025-09-300001958086us-gaap:ProductMember2025-07-012025-09-300001958086clb:TwoThousandTwentyOneSeniorNotesSeriesBMember2025-01-012025-09-300001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:IntersegmentEliminationMember2025-07-012025-09-300001958086us-gaap:TreasuryStockCommonMember2024-09-300001958086currency:RUB2025-07-012025-09-300001958086us-gaap:CommonStockMember2025-09-300001958086us-gaap:SeriesAMemberclb:TwoThousandTwentyThreeSeniorNotesMember2025-01-012025-09-300001958086clb:CommonStockOutstandingMember2025-06-300001958086us-gaap:IntersegmentEliminationMemberclb:OperatingSegmentReservoirDescriptionMember2024-01-012024-09-300001958086currency:SEK2024-07-012024-09-300001958086us-gaap:RetainedEarningsMember2025-01-012025-09-300001958086srt:OtherCurrencyMember2024-01-012024-09-300001958086clb:SolintecConsultoriaEServicosDeGeologiaLtdMemberus-gaap:SubsequentEventMember2025-10-010001958086clb:InterestRateSwapNo2Member2024-01-012024-09-300001958086us-gaap:OperatingSegmentsMemberclb:OperatingSegmentReservoirDescriptionMember2024-09-300001958086us-gaap:NoncontrollingInterestMember2024-09-300001958086us-gaap:TreasuryStockCommonMember2025-06-300001958086us-gaap:OperatingSegmentsMember2024-07-012024-09-300001958086clb:TwoThousandTwentyThreeSeniorNotesSeriesAMember2025-01-012025-09-300001958086us-gaap:NoncontrollingInterestMember2023-12-310001958086us-gaap:SeriesAMemberclb:TwoThousandTwentyOneSeniorNotesMember2025-09-300001958086srt:MinimumMemberclb:TwoThousandTwentyThreeSeniorNotesMember2023-06-280001958086us-gaap:FairValueInputsLevel2Member2024-12-310001958086currency:RUB2024-07-012024-09-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:OperatingSegmentsMember2025-09-300001958086us-gaap:ProductMember2024-01-012024-09-300001958086us-gaap:DelayedDrawTermLoanMember2025-07-222025-07-220001958086us-gaap:DelayedDrawTermLoanMember2025-07-220001958086us-gaap:InterestRateSwapMember2025-01-012025-09-300001958086currency:COP2024-07-012024-09-3000019580862024-07-012024-09-300001958086currency:CAD2024-01-012024-09-300001958086clb:CommonStockOutstandingMember2024-09-300001958086us-gaap:TreasuryStockCommonMember2023-12-310001958086srt:MinimumMember2025-07-220001958086clb:TwoThousandTwentyThreeSeniorNotesSeriesAMember2025-09-300001958086currency:GBP2025-01-012025-09-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-09-300001958086us-gaap:SeriesAMemberclb:TwoThousandTwentyOneSeniorNotesMember2024-12-310001958086us-gaap:RetainedEarningsMember2025-06-300001958086us-gaap:OperatingSegmentsMemberus-gaap:CorporateAndOtherMember2024-09-300001958086us-gaap:RetainedEarningsMember2024-12-310001958086us-gaap:ProductMember2025-01-012025-09-300001958086us-gaap:AdditionalPaidInCapitalMember2025-06-300001958086us-gaap:NoncontrollingInterestMember2025-09-300001958086srt:MinimumMember2025-01-012025-09-300001958086clb:TwoThousandTwentyOneSeniorNotesMemberus-gaap:SeriesBMember2025-09-300001958086us-gaap:ProductMember2024-07-012024-09-300001958086clb:CommonStockOutstandingMember2025-07-012025-09-300001958086us-gaap:OperatingSegmentsMemberclb:OperatingSegmentReservoirDescriptionMember2025-01-012025-09-300001958086us-gaap:AdditionalPaidInCapitalMember2024-12-310001958086currency:COP2025-07-012025-09-300001958086currency:COP2024-01-012024-09-300001958086clb:InterestRateSwapNo1Member2024-01-012024-09-300001958086clb:TwoThousandTwentyThreeSeniorNotesMember2023-06-280001958086us-gaap:NoncontrollingInterestMember2024-12-3100019580862024-09-300001958086us-gaap:TreasuryStockCommonMember2024-06-300001958086currency:EUR2024-07-012024-09-300001958086us-gaap:RetainedEarningsMember2024-01-012024-09-300001958086us-gaap:OperatingSegmentsMemberus-gaap:CorporateAndOtherMember2025-01-012025-09-300001958086us-gaap:OperatingSegmentsMemberus-gaap:CorporateAndOtherMember2025-09-300001958086clb:ForwardInterestRateSwapMember2025-09-300001958086us-gaap:IntersegmentEliminationMemberclb:OperatingSegmentReservoirDescriptionMember2024-07-012024-09-300001958086us-gaap:CommonStockMember2023-12-310001958086us-gaap:TreasuryStockCommonMember2025-01-012025-09-300001958086us-gaap:NoncontrollingInterestMember2025-06-300001958086us-gaap:InterestRateSwapMember2024-07-012024-09-300001958086us-gaap:OperatingSegmentsMemberus-gaap:CorporateAndOtherMember2024-07-012024-09-300001958086us-gaap:OperatingSegmentsMember2025-07-012025-09-300001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:IntersegmentEliminationMember2024-01-012024-09-300001958086currency:IDR2024-01-012024-09-300001958086us-gaap:RetainedEarningsMember2024-09-3000019580862025-07-220001958086us-gaap:NoncontrollingInterestMember2025-07-012025-09-300001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:IntersegmentEliminationMember2025-01-012025-09-300001958086us-gaap:IntersegmentEliminationMember2025-01-012025-09-300001958086clb:InterestRateSwapNo1Member2024-07-012024-09-300001958086us-gaap:RetainedEarningsMember2025-09-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:OperatingSegmentsMember2024-09-300001958086us-gaap:ServiceMember2024-01-012024-09-3000019580862025-07-012025-09-300001958086clb:InterestRateSwapNo2Member2025-01-012025-09-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001958086clb:CommonStockOutstandingMember2025-09-300001958086us-gaap:IntersegmentEliminationMember2024-07-012024-09-300001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:OperatingSegmentsMember2025-01-012025-09-300001958086us-gaap:IntersegmentEliminationMemberus-gaap:CorporateAndOtherMember2024-01-012024-09-3000019580862023-12-3100019580862024-01-012024-09-300001958086currency:GBP2024-07-012024-09-3000019580862025-01-012025-09-300001958086us-gaap:NoncontrollingInterestMember2025-01-012025-09-300001958086clb:TwoThousandTwentyOneSeniorNotesMemberus-gaap:SeriesBMember2024-12-310001958086clb:FireIncidentMember2025-07-012025-09-300001958086us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001958086us-gaap:IntersegmentEliminationMemberus-gaap:CorporateAndOtherMember2025-01-012025-09-300001958086currency:EUR2025-07-012025-09-300001958086clb:CommonStockOutstandingMember2024-01-012024-09-300001958086currency:CAD2025-01-012025-09-300001958086us-gaap:TreasuryStockCommonMember2025-07-012025-09-300001958086us-gaap:NoncontrollingInterestMember2024-06-300001958086us-gaap:RetainedEarningsMember2024-06-3000019580862025-07-012025-09-300001958086us-gaap:ServiceMember2025-07-012025-09-300001958086us-gaap:NoncontrollingInterestMember2024-01-012024-09-300001958086us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001958086us-gaap:ServiceMember2025-01-012025-09-300001958086us-gaap:IntersegmentEliminationMemberclb:OperatingSegmentReservoirDescriptionMember2025-07-012025-09-300001958086clb:CommonStockOutstandingMember2023-12-310001958086currency:SEK2025-07-012025-09-300001958086clb:TwoThousandTwentyThreeSeniorNotesMembersrt:MaximumMember2023-06-280001958086clb:CommonStockOutstandingMember2024-07-012024-09-300001958086us-gaap:IntersegmentEliminationMember2024-01-012024-09-3000019580862024-06-300001958086currency:IDR2025-01-012025-09-300001958086srt:OtherCurrencyMember2025-01-012025-09-300001958086clb:TwoThousandTwentyOneSeniorNotesMemberus-gaap:SeriesBMember2025-01-012025-09-300001958086us-gaap:ServiceMember2024-07-012024-09-300001958086us-gaap:LineOfCreditMember2025-09-300001958086us-gaap:OperatingSegmentsMemberclb:OperatingSegmentReservoirDescriptionMember2025-07-012025-09-300001958086us-gaap:SubsequentEventMemberclb:O2025Q4DividendsMember2025-10-222025-10-220001958086us-gaap:LineOfCreditMember2024-12-310001958086currency:IDR2025-07-012025-09-300001958086currency:EUR2024-01-012024-09-300001958086srt:OtherCurrencyMember2025-07-012025-09-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-3000019580862025-10-170001958086us-gaap:TreasuryStockCommonMember2024-12-310001958086currency:CAD2024-07-012024-09-300001958086us-gaap:AdditionalPaidInCapitalMember2023-12-310001958086currency:SEK2025-01-012025-09-300001958086clb:CommonStockOutstandingMember2025-01-012025-09-3000019580862025-09-300001958086clb:TwoThousandTwentyOneSeniorNotesSeriesBMember2025-09-300001958086us-gaap:FairValueInputsLevel2Member2025-09-300001958086clb:InterestRateSwapNo2Member2024-07-012024-09-300001958086us-gaap:RevolvingCreditFacilityMember2025-07-220001958086us-gaap:TreasuryStockCommonMember2024-01-012024-09-300001958086us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001958086us-gaap:AdditionalPaidInCapitalMember2024-09-300001958086srt:MaximumMember2025-01-012025-09-300001958086us-gaap:AdditionalPaidInCapitalMember2024-06-300001958086us-gaap:SubsequentEventMember2025-10-222025-10-220001958086clb:InterestRateSwapNo1Member2025-01-012025-09-300001958086us-gaap:InterestRateSwapMember2025-07-012025-09-300001958086clb:TwoThousandTwentyThreeSeniorNotesMemberus-gaap:SeriesBMember2025-09-300001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:OperatingSegmentsMember2024-01-012024-09-300001958086us-gaap:IntersegmentEliminationMemberclb:OperatingSegmentReservoirDescriptionMember2025-01-012025-09-300001958086us-gaap:SeriesAMemberclb:TwoThousandTwentyOneSeniorNotesMember2025-01-012025-09-300001958086us-gaap:RetainedEarningsMember2025-07-012025-09-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001958086currency:RUB2025-01-012025-09-300001958086us-gaap:OperatingSegmentsMember2025-01-012025-09-3000019580862024-12-310001958086currency:GBP2024-01-012024-09-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001958086clb:InterestRateSwapNo2Member2025-07-012025-09-300001958086us-gaap:OperatingSegmentsMemberclb:OperatingSegmentReservoirDescriptionMember2024-01-012024-09-300001958086us-gaap:RetainedEarningsMember2023-12-310001958086clb:InterestRateSwapNo1Member2025-07-012025-09-300001958086us-gaap:RetainedEarningsMember2024-07-012024-09-300001958086us-gaap:AdditionalPaidInCapitalMember2025-09-300001958086us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001958086us-gaap:InterestRateSwapMember2024-01-012024-09-300001958086us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-300001958086us-gaap:IntersegmentEliminationMemberus-gaap:CorporateAndOtherMember2024-07-012024-09-300001958086currency:GBP2025-07-012025-09-300001958086srt:OtherCurrencyMember2024-07-012024-09-300001958086clb:CommonStockOutstandingMember2024-06-300001958086clb:CommonStockOutstandingMember2024-12-310001958086us-gaap:OperatingSegmentsMember2024-01-012024-09-300001958086clb:ForwardInterestRateSwapMember2025-01-012025-09-300001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:OperatingSegmentsMember2024-07-012024-09-300001958086us-gaap:CommonStockMember2024-06-300001958086us-gaap:OperatingSegmentsMemberus-gaap:CorporateAndOtherMember2024-01-012024-09-300001958086us-gaap:SeriesAMemberclb:TwoThousandTwentyThreeSeniorNotesMember2025-09-300001958086us-gaap:LineOfCreditMembersrt:MaximumMember2025-09-300001958086currency:IDR2024-07-012024-09-300001958086us-gaap:OperatingSegmentsMemberclb:OperatingSegmentReservoirDescriptionMember2024-07-012024-09-300001958086clb:TwoThousandTwentyThreeSeniorNotesMemberus-gaap:SeriesBMember2025-01-012025-09-300001958086us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001958086us-gaap:CommonStockMember2025-06-300001958086us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001958086us-gaap:SeriesAMemberclb:TwoThousandTwentyThreeSeniorNotesMember2024-12-310001958086clb:OperatingSegmentProductionEnhancementMemberus-gaap:IntersegmentEliminationMember2024-07-012024-09-300001958086currency:SEK2024-01-012024-09-30xbrli:purexbrli:sharesclb:Segmentiso4217:USDiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ______________

Commission File Number: 001-41695

CORE LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Delaware		98-1164194
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
6316 Windfern Road
Houston, TX		77040
(Address of principal executive offices)		(Zip Code)

(713) 328-2673

(Registrant's telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock (par value $0.01)		CLB		New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of common stock of the registrant, par value $0.01 per share, outstanding at October 17, 2025 was 46,563,387.

CORE LABORATORIES INC.

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2025

INDEX

PART I - FINANCIAL INFORMATION

		Page
Item 1.	Financial Statements
	Consolidated Balance Sheets at September 30, 2025 (Unaudited) and December 31, 2024	3
	Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)	4
	Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)	6
	Consolidated Statements of Changes in Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)	7
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited)	9
	Notes to the Interim Consolidated Financial Statements (Unaudited)	10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4.	Controls and Procedures	35
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	35
Item 1A.	Risk Factors	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 5.	Other Information	37
Item 6.	Exhibits	38
	Signature	39

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CORE LABORATORIES INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

		September 30, 2025				December 31, 2024
		(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	25,629			$	19,157
Accounts receivable, net of allowance for credit losses       of $5,296 and $3,192 at 2025 and 2024, respectively			110,258				111,761
Inventories			58,241				59,402
Prepaid expenses			10,056				10,176
Income taxes receivable			14,716				15,594
Other current assets			8,014				10,516
TOTAL CURRENT ASSETS			226,914				226,606
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation       of $321,113 and $314,317 at 2025 and 2024, respectively			98,031				97,063
RIGHT OF USE ASSETS			53,980				56,488
INTANGIBLES, net of accumulated amortization and impairment       of $19,470 and $19,326 at 2025 and 2024, respectively			6,107				6,403
GOODWILL			100,012				99,445
DEFERRED TAX ASSETS, net			70,506				69,613
OTHER ASSETS			35,810				34,788
TOTAL ASSETS		$	591,360			$	590,406
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable		$	36,945			$	34,549
Accrued payroll and related costs			23,363				22,901
Taxes other than payroll and income			3,852				7,106
Unearned revenues			7,258				9,332
Operating lease liabilities			11,474				10,690
Income taxes payable			3,513				4,851
Other current liabilities			9,338				8,157
TOTAL CURRENT LIABILITIES			95,743				97,586
LONG-TERM DEBT, net			114,103				126,111
LONG-TERM OPERATING LEASE LIABILITIES			41,525				43,343
DEFERRED COMPENSATION			31,054				31,115
DEFERRED TAX LIABILITIES, net			10,102				13,783
OTHER LONG-TERM LIABILITIES			21,445				20,732
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding			—				—
Common stock, 200,000,000 shares authorized, $0.01 par value,  46,966,868 issued and 46,086,944 outstanding at 2025; 46,966,868 issued and 46,826,820 outstanding at 2024			470				470
Additional paid-in capital			113,874				109,547
Retained earnings			173,598				150,280
Accumulated other comprehensive income (loss)			(5,984	)			(5,769	)
Treasury stock (at cost), 879,924 and 140,048 shares at 2025 and 2024, respectively			(10,611	)			(2,537	)
Total Core Laboratories Inc. shareholders' equity			271,347				251,991
Non-controlling interest			6,041				5,745
TOTAL EQUITY			277,388				257,736
TOTAL LIABILITIES AND EQUITY		$	591,360			$	590,406

The accompanying notes are an integral part of these interim consolidated financial statements.

3

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

		Three Months Ended
		September 30,
		2025				2024
		(Unaudited)
REVENUE:
Services		$	101,125			$	98,842
Product sales			33,396				35,555
Total revenue			134,521				134,397
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below			74,896				75,503
Cost of product sales, exclusive of depreciation expense shown below			30,005				31,302
General and administrative expense, exclusive of depreciation expense shown below			10,688				8,642
Depreciation			3,529				3,551
Amortization			65				125
Other (income) expense, net			(5,590	)			(4,529	)
OPERATING INCOME			20,928				19,803
Interest expense			2,650				3,108
Income before income taxes			18,278				16,695
Income tax expense			3,754				4,691
Net income			14,524				12,004
Net income attributable to non-controlling interest			285				259
Net income attributable to Core Laboratories Inc.		$	14,239			$	11,745
EARNINGS PER SHARE INFORMATION:
Basic earnings per share		$	0.31			$	0.26
Basic earnings per share attributable to Core Laboratories Inc.		$	0.31			$	0.25
Diluted earnings per share		$	0.31			$	0.25
Diluted earnings per share attributable to Core Laboratories Inc.		$	0.30			$	0.25
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic			46,263				46,922
Diluted			47,078				47,820

The accompanying notes are an integral part of these interim consolidated financial statements.

4

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

		Nine Months Ended
		September 30,
		2025				2024
		(Unaudited)
REVENUE:
Services		$	292,435			$	291,674
Product sales			95,830				102,937
Total revenue			388,265				394,611
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below			221,929				224,191
Cost of product sales, exclusive of depreciation expense shown below			86,142				90,132
General and administrative expense, exclusive of depreciation expense shown below			34,799				30,690
Depreciation			10,683				10,909
Amortization			298				380
Other (income) expense, net			(6,222	)			(6,073	)
OPERATING INCOME			40,636				44,382
Interest expense			7,963				9,740
Income before income taxes			32,673				34,642
Income tax expense			7,411				9,958
Net income			25,262				24,684
Net income attributable to non-controlling interest			541				687
Net income attributable to Core Laboratories Inc.		$	24,721			$	23,997
EARNINGS PER SHARE INFORMATION:
Basic earnings per share		$	0.54			$	0.53
Basic earnings per share attributable to Core Laboratories Inc.		$	0.53			$	0.51
Diluted earnings per share		$	0.53			$	0.52
Diluted earnings per share attributable to Core Laboratories Inc.		$	0.52			$	0.50
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic			46,552				46,897
Diluted			47,381				47,690

The accompanying notes are an integral part of these interim consolidated financial statements.

5

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
		(Unaudited)
Net income		$	14,524			$	12,004			$	25,262			$	24,684
Other comprehensive income (loss):
Interest rate swaps:
Interest rate swap amount reclassified to net income			(108	)			(235	)			(489	)			(780	)
Income tax benefit on interest rate swaps reclassified to net income			24				50				103				164
Total interest rate swaps			(84	)			(185	)			(386	)			(616	)
Pension and other postretirement benefit plans:
Amortization of actuarial gain reclassified to net income			77				63				232				191
Income tax expense on pension and other postretirement benefit plans reclassified to net income			(20	)			(15	)			(61	)			(49	)
Total pension and other postretirement benefit plans			57				48				171				142
Total other comprehensive income (loss)			(27	)			(137	)			(215	)			(474	)
Comprehensive income			14,497				11,867				25,047				24,210
Comprehensive income attributable to non-controlling interest			285				259				541				687
Comprehensive income attributable to Core Laboratories Inc.		$	14,212			$	11,608			$	24,506			$	23,523

The accompanying notes are an integral part of these interim consolidated financial statements.

6

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(In thousands, except share and per share data)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
		(Unaudited)
Common Stock
Balance at Beginning of Period		$	470			$	469			$	470			$	469
Balance at End of Period		$	470			$	469			$	470			$	469
Additional Paid-In Capital
Balance at Beginning of Period		$	112,763			$	113,479			$	109,547			$	110,011
Stock-based compensation			1,111				(869	)			4,327				2,599
Balance at End of Period		$	113,874			$	112,610			$	113,874			$	112,610
Retained Earnings
Balance at Beginning of Period		$	159,824			$	132,070			$	150,280			$	120,756
Dividends paid			(465	)			(469	)			(1,403	)			(1,407	)
Net income attributable to Core Laboratories Inc.			14,239				11,745				24,721				23,997
Balance at End of Period		$	173,598			$	143,346			$	173,598			$	143,346
Accumulated Other Comprehensive Income (Loss)
Balance at Beginning of Period		$	(5,957	)		$	(5,309	)		$	(5,769	)		$	(4,972	)
Interest rate swaps, net of income taxes			(84	)			(185	)			(386	)			(616	)
Pension and other postretirement benefit plans, net of income taxes			57				48				171				142
Balance at End of Period		$	(5,984	)		$	(5,446	)		$	(5,984	)		$	(5,446	)
Treasury Stock
Balance at Beginning of Period		$	(5,817	)		$	(435	)		$	(2,537	)		$	(1,449	)
Stock-based compensation			215				394				1,696				1,614
Repurchase of common stock			(5,009	)			(196	)			(9,770	)			(402	)
Balance at End of Period		$	(10,611	)		$	(237	)		$	(10,611	)		$	(237	)
Non-Controlling Interest
Balance at Beginning of Period		$	6,020			$	5,420			$	5,745			$	4,992
Non-controlling interest contribution			—				—				19				—
Non-controlling interest dividend			(264	)			—				(264	)			—
Net income attributable to non-controlling interest			285				259				541				687
Balance at End of Period		$	6,041			$	5,679			$	6,041			$	5,679
Total Equity
Balance at Beginning of Period		$	267,303			$	245,694			$	257,736			$	229,807
Stock-based compensation			1,326				(475	)			6,023				4,213
Non-controlling interest contribution			—				—				19				—
Non-controlling interest dividend			(264	)			—				(264	)			—
Dividends paid			(465	)			(469	)			(1,403	)			(1,407	)
Net income			14,524				12,004				25,262				24,684
Interest rate swaps, net of income taxes			(84	)			(185	)			(386	)			(616	)
Pension and other postretirement benefit plans, net of income taxes			57				48				171				142
Repurchase of common stock			(5,009	)			(196	)			(9,770	)			(402	)
Balance at End of Period		$	277,388			$	256,421			$	277,388			$	256,421
Cash Dividends per Share		$	0.01			$	0.01			$	0.03			$	0.03

The accompanying notes are an integral part of these interim consolidated financial statements.

7

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Continued)

(In thousands, except share and per share data)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
		(Unaudited)
Common Stock - Number of shares issued
Balance at Beginning of Period			46,966,868				46,938,557				46,966,868				46,938,557
Balance at End of Period			46,966,868				46,938,557				46,966,868				46,938,557
Treasury Stock - Number of shares
Balance at Beginning of Period			(430,078	)			(25,862	)			(140,048	)			(82,021	)
Stock-based compensation			12,402				23,242				91,602				92,313
Repurchase of common stock			(462,248	)			(8,546	)			(831,478	)			(21,458	)
Balance at End of Period			(879,924	)			(11,166	)			(879,924	)			(11,166	)
Common Stock - Number of shares outstanding
Balance at Beginning of Period			46,536,790				46,912,695				46,826,820				46,856,536
Stock-based compensation			12,402				23,242				91,602				92,313
Repurchase of common stock			(462,248	)			(8,546	)			(831,478	)			(21,458	)
Balance at End of Period			46,086,944				46,927,391				46,086,944				46,927,391

The accompanying notes are an integral part of these interim consolidated financial statements.

8

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

		Nine Months Ended
		September 30,
		2025				2024
		(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	25,262			$	24,684
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation			6,023				4,213
Depreciation and amortization			10,981				11,289
Assets write-down			34				1,110
Inventory write-off and obsolescence			2,429				1,015
Provision for credit losses			2,152				1,222
Changes in value of life insurance policies			(1,851	)			(3,188	)
Deferred income taxes			(4,573	)			102
Insurance recovery on property, plant and equipment			(6,830	)			(2,102	)
Other non-cash items			852				256
Changes in assets and liabilities:
Accounts receivable			(615	)			(9,461	)
Inventories			(1,268	)			5,197
Prepaid expenses and other current assets			(797	)			(4,357	)
Other assets			(351	)			(205	)
Accounts payable			1,284				(373	)
Accrued expenses			(3,370	)			2,392
Unearned revenues			(2,074	)			2,453
Other liabilities			1,797				1,526
Net cash provided by operating activities			29,085				35,773
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures - operations			(8,265	)			(8,647	)
Capital expenditures - rebuilding of Aberdeen facility			(2,672	)			—
Proceeds from insurance recovery - Aberdeen facility			9,951				2,102
Patents and other intangibles			(2	)			—
Acquisitions, net of cash acquired			(617	)			—
Proceeds from sale of assets			2,348				934
Net proceeds on life insurance policies			778				2,776
Net cash provided by (used in) investing activities			1,521				(2,835	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of long-term debt			(47,000	)			(62,000	)
Proceeds from long-term debt			36,000				38,000
Debt issuance costs			(1,706	)			—
Dividends paid			(1,403	)			(1,407	)
Repurchase of common stock			(9,770	)			(402	)
Equity related transaction costs			—				(756	)
Other financing activity			(255	)			(19	)
Net cash used in financing activities			(24,134	)			(26,584	)
NET CHANGE IN CASH AND CASH EQUIVALENTS			6,472				6,354
CASH AND CASH EQUIVALENTS, beginning of period			19,157				15,120
CASH AND CASH EQUIVALENTS, end of period		$	25,629			$	21,474
Supplemental disclosures of cash flow information:
Cash payments for interest		$	6,553			$	8,741
Cash payments for income taxes		$	9,535			$	11,892
Non-cash investing and financing activities:
Capital expenditures incurred but not paid for as of the end of the period		$	1,006			$	1,591

The accompanying notes are an integral part of these interim consolidated financial statements.

9

Return to Index

CORE LABORATORIES INC.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. DESCRIPTION OF BUSINESS

References to “Core Lab”, “Core Laboratories”, the “Company”, “we”, “our” and similar phrases are used throughout this Quarterly Report on Form 10-Q (“Quarterly Report”) and relate collectively to Core Laboratories Inc. and its consolidated subsidiaries.

We operate our business in two segments: (1) Reservoir Description and (2) Production Enhancement. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. For a description of the types of services and products offered by these operating segments, see Note 16 - Segment Reporting.

2. SIGNIFICANT ACCOUNTING POLICIES UPDATE

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim consolidated financial statements include the accounts of Core Laboratories Inc. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP for the annual financial statements and should be read in conjunction with the audited financial statements and notes thereto included in Core Laboratories Inc.’s Annual Report on Form 10-K for the year ended December 31, 2024, including Note 2 - Summary of Significant Accounting Policies. Core Laboratories Inc.’s balance sheet information for the year ended December 31, 2024, was derived from the 2024 audited consolidated financial statements. There have been no changes to the accounting policies during the nine months ended September 30, 2025.

Core Laboratories Inc. uses the equity method of accounting for investments in which it has less than a majority interest and does not exercise control but does exert significant influence. Non-controlling interests have been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned. All inter-company transactions and balances have been eliminated in consolidation.

In the opinion of management, all adjustments considered necessary for a fair statement of the results for the interim periods presented have been included in these financial statements. Furthermore, the operating results presented for the three and nine months ended September 30, 2025, may not necessarily be indicative of the results that may be expected for the year ending December 31, 2025.

Certain reclassifications were made to prior period amounts in order to conform to the current period presentations. These reclassifications had no impact on the reported net income or cash flows for the three and nine months ended September 30, 2024.

Property, Plant and Equipment

We review our long-lived assets (“LLA”) for impairment when events or changes in circumstances indicate that their net book value may not be recovered over their remaining service lives. Indicators of possible impairment may include significant declines in activity levels in regions where specific assets or groups of assets are located, extended periods of idle use, declining revenue or cash flow or overall changes in general market conditions.

The geopolitical conflict between Russia and Ukraine, which began in February 2022 and has continued through September 30, 2025, has resulted in disruptions to our operations in Russia and Ukraine. As of September 30, 2025, our

10

Return to Index

laboratory facilities, offices, and locations in Russia and Ukraine continued to operate with no significant impact to local business operations. Therefore, we determined there was no triggering event for LLA impairment in Russia and Ukraine, and no impairment assessments have been performed as of September 30, 2025.

Recent Accounting Pronouncements

Issued But Not Yet Effective

In December 2023, FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures to improve transparency of income tax disclosures, primarily by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The amendment is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The amendment should be applied prospectively; however, retrospective application is permitted. Upon adoption, our disclosures regarding income taxes will be expanded accordingly.

In November 2024, FASB issued ASU 2024-03 Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40) to improve disclosures about a public business entity’s expenses, by providing more detailed information about the types of expenses in commonly presented expense captions. As amended by ASU 2025-01 issued in January 2025, the amendment is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendment may be applied prospectively or retrospectively. Upon adoption, our disclosures regarding expenses will be expanded.

In July 2025, FASB issued ASU 2025-05 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which allows public business entities to apply a practical expedient when estimating expected credit losses that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The amendment is effective for annual and interim periods beginning after December 15, 2025. Early adoption is permitted. The amendment will be applied prospectively. Upon adoption, our disclosures regarding estimating expected credit losses will be expanded.

3. ACQUISITIONS AND DIVESTURES

We had no significant business acquisitions or divestures during the three and nine months ended September 30, 2025 and 2024.

Subsequent to the quarter ending September 30, 2025, on October 1, 2025, we acquired 100% of the equity interests in Solintec Consultoria E Servicos De Geologia Ltda., a Brazilian limited liability company and a leading provider of geological services to the region’s oil and gas industry. The acquisition is included in our Reservoir Description operating segment.

The total purchase price is comprised of an initial cash payment of $2.3 million plus up to $3.7 million of additional contingent cash consideration, payable in annual installments, provided certain performance targets are achieved over the two-year period following closing.

We have not finalized the assessment of the fair values of assets acquired, including intangible assets, and liabilities assumed or the resulting goodwill and its taxability. Fair value estimates of certain assets and liabilities require more current financial information or are based on significant judgments and assumptions. Our estimates of acquisition date fair value will be adjusted where required as additional information is received during the measurement period subsequent to the acquisition date, not to exceed one year.

4. CONTRACT ASSETS AND LIABILITIES

The balance of contract assets and liabilities consisted of the following (in thousands):

11

Return to Index

		September 30, 2025				December 31, 2024
Contract assets:
Current		$	1,162			$	370
		$	1,162			$	370
Contract liabilities:
Current		$	426			$	560
		$	426			$	560

		September 30, 2025
Estimate of when contract liabilities will be recognized as revenue:
Within 12 months		$	426

The current portion of contract assets is included in our accounts receivable. The current portion of contract liabilities is included in unearned revenues and, as applicable, the non-current portion of contract liabilities is included in other long-term liabilities.

We did not recognize any impairment losses on our contract assets during the three and nine months ended September 30, 2025 and 2024.

5. INVENTORIES

Inventories consist of the following (in thousands):

		September 30, 2025				December 31, 2024
Finished goods		$	28,940			$	27,127
Parts and materials			26,525				28,953
Work in progress			2,776				3,322
Total inventories		$	58,241			$	59,402

We include freight costs incurred for shipping inventory to our clients in the cost of product sales caption in the accompanying consolidated statements of operations.

6. LEASES

We have operating leases primarily consisting of office and lab space, machinery and equipment and vehicles. We entered into a sublease agreement in 2023 that was terminated at the beginning of 2025, for existing office and lab space in Calgary, Alberta, Canada.

12

Return to Index

The components of lease expense and other information are as follows (in thousands):

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
Consolidated Statements of Operations:
Operating lease expense		$	4,243			$	4,296			$	12,589			$	12,942
Short-term lease expense			453				393				1,334				1,230
Variable lease expense			425				212				1,284				1,032
Sublease income			—				(56	)			—				(169	)
Total lease expense		$	5,121			$	4,845			$	15,207			$	15,035
Consolidated Statements of Cash Flows:
Operating cash flows - operating leases payments		$	3,927			$	3,882			$	12,822			$	12,791
Right of use assets obtained (released) in exchange for operating lease obligations		$	2,184			$	3,647			$	7,060			$	10,606
Other information:
Weighted-average remaining lease term - operating leases		8.19 years				8.40 years				8.19 years				8.40 years
Weighted-average discount rate - operating leases			5.48	%			5.41	%			5.48	%			5.41	%

Scheduled undiscounted lease payments for non-cancellable operating leases consist of the following (in thousands):

		September 30, 2025
		Operating Leases
Remainder of 2025		$	3,786
2026			12,927
2027			10,140
2028			7,903
2029			5,330
Thereafter			26,146
Total undiscounted lease payments			66,232
Less: Imputed interest			(13,233	)
Total operating lease liabilities		$	52,999

7. LONG-TERM DEBT, NET

We have no finance lease obligations. Debt is summarized in the following table (in thousands):

	Interest Rate		Maturity Date		September 30, 2025				December 31, 2024
Credit Facility					$	7,000			$	18,000
2021 Senior Notes Series A (1)	4.09%		January 12, 2026			45,000				45,000
2021 Senior Notes Series B (1)	4.38%		January 12, 2028			15,000				15,000
2023 Senior Notes Series A (2)	7.25%		June 28, 2028			25,000				25,000
2023 Senior Notes Series B (2)	7.50%		June 28, 2030			25,000				25,000
Total long-term debt						117,000				128,000
Less: Debt issuance costs						(2,897	)			(1,889	)
Long-term debt, net					$	114,103			$	126,111

(1) Interest is payable semi-annually on June 30 and December 30.

(2) Interest is payable semi-annually on March 28 and September 28.

On July 22, 2025, we, along with our direct subsidiary Core Laboratories (U.S.) Interests Holdings, Inc. (“CLIH”) entered into the Ninth Amended and Restated Credit Agreement (as amended, the “Credit Facility”) for an aggregate borrowing commitment of $150.0 million with a $50.0 million “accordion” feature. Draws up to $100.0 million are available in the form of a revolving credit facility, and a single draw of $50.0 million is available in the form of a delayed draw term loan (“DDTL”)

13

Return to Index

through January 12, 2026. The DDTL is repayable in quarterly installments of $625 thousand and prepayments are permitted without penalty. Any remaining outstanding balances under the revolving credit facility and the DDTL are due at maturity on July 22, 2029, subject to springing maturity dates unless the Company’s liquidity equals or exceeds the principal amount of each of the respective senior notes series that remain outstanding on each of the respective springing maturity dates as follows:

(1)October 14, 2027, if any portion of the Company’s 2021 Senior Notes Series B due January 12, 2028, in the aggregate principal amount of $15.0 million, remains outstanding on October 14, 2027, and

(2)March 30, 2028, if any portion of the Company’s 2023 Senior Notes Series A due June 28, 2028, in the aggregate principal amount of $25.0 million, remains outstanding on March 30, 2028.

There are no significant changes to other terms from the Eighth Amended and Restated Credit Agreement, including assets securing the debt, interest rates, and cross default provisions associated with the Senior Notes (as defined below), financial covenants or the interest coverage and leverage ratios as described below.

The Credit Facility is secured by first priority interests in (1) substantially all of the tangible and intangible personal property, and equity interest of CLIH and certain of the Company’s U.S. and foreign subsidiary companies and (2) instruments evidencing intercompany indebtedness owing to the Company, CLIH and certain of the Company’s U.S. and foreign subsidiary companies. Certain of our significant, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes.

Under the Credit Facility, the Secured Overnight Financing Rate (“SOFR”) plus 2.00% to SOFR plus 3.00% will be applied to outstanding borrowings. The available capacity at any point in time is reduced by outstanding borrowings and outstanding letters of credit which totaled approximately $11.1 million at September 30, 2025, resulting in an available borrowing capacity under the Credit Facility of approximately $131.9 million. In addition to indebtedness under the Credit Facility, we had approximately $8.0 million of outstanding letters of credit and performance guarantees and bonds from other sources as of September 30, 2025.

The Credit Facility and Senior Notes include a cross-default provision, whereby a default under one agreement may trigger a default in the other agreements.

The terms of the Credit Facility and Senior Notes require us to meet certain covenants, including, but not limited to, an interest coverage ratio (calculated as consolidated EBITDA divided by interest expense) and a leverage ratio (calculated as consolidated net indebtedness divided by consolidated EBITDA), where consolidated EBITDA (as defined in each agreement) and interest expense are calculated using the most recent four fiscal quarters. The Credit Facility has more restrictive covenants with a minimum interest coverage ratio of 3.00 to 1.00 and permits a maximum leverage ratio of 2.50 to 1.00. The Credit Facility allows non-cash charges such as impairment of assets, stock compensation and other non-cash charges to be added back in the calculation of consolidated EBITDA. The terms of our Credit Facility also allow us to negotiate in good faith to amend any ratio or requirement to preserve the original intent of the agreement if any change in accounting principles would affect the computation of any financial ratio or covenant of the Credit Facility. In accordance with the terms of the Credit Facility, our leverage ratio is 1.10 and our interest coverage ratio is 7.86, each for the period ended September 30, 2025. We are in compliance with all covenants contained in our Credit Facility and Senior Notes as of September 30, 2025.

We, along with CLIH as issuer, have senior notes outstanding that were issued through private placement transactions. Series A and Series B of the 2021 Senior Notes were issued in 2021 (the “2021 Senior Notes”). Series A and Series B of the 2023 Senior Notes were issued in 2023 (the “2023 Senior Notes”). The 2021 Senior Notes and the 2023 Senior Notes are collectively the “Senior Notes”. We intend to repay the 2021 Senior Notes Series A at maturity in January 2026 using borrowings under the Credit Facility; therefore, we continue to classify them as long-term debt.

See Note 11 - Derivative Instruments and Hedging Activities for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our Senior Notes.

14

Return to Index

The estimated fair value of total debt at September 30, 2025 and December 31, 2024, approximated the book value of total debt. The fair value was estimated using Level 2 inputs by calculating the sum of the discounted future interest and principal payments through the maturity date.

8. PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS

Prior to January 2020, one of our subsidiaries provided a noncontributory defined benefit pension plan covering substantially all of our Dutch employees (“Dutch Plan”) who were hired prior to 2000. This pension benefit was based on years of service and final pay or career average pay, depending on when the employee began participating. The Dutch Plan was curtailed prior to January 2020, and these employees have been moved into the Dutch defined contribution plan. However, the unconditional indexation for this group of participants continues for so long as they remain in active service with the Company.

The following table summarizes the components of net periodic pension cost under the Dutch Plan (in thousands):

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
Interest cost		$	386			$	352			$	1,106			$	1,054
Expected return on plan assets			(312	)			(314	)			(893	)			(891	)
Net periodic pension cost		$	74			$	38			$	213			$	163

9. COMMITMENTS AND CONTINGENCIES

We have been and may, from time to time, be named as a defendant in legal actions that arise in the ordinary course of business. These include, but are not limited to, employment-related claims and contractual disputes or claims for personal injury or property damage which occur in connection with the provision of our services and products. A liability is accrued when a loss is both probable and can be reasonably estimated.

See Note 7 - Long-term Debt, net for amounts committed under letters of credit and performance guarantees and bonds.

10. EQUITY

Treasury Stock

During the three and nine months ended September 30, 2025, we distributed 12,402 and 91,602 shares, respectively, of treasury stock upon vesting of stock-based awards. During the three and nine months ended September 30, 2025, we repurchased 462,248 and 831,478 shares, respectively, of our common stock for $5.0 million and $9.8 million, respectively. The total repurchased shares include rights which were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participant’s tax burdens resulting from the issuance of common stock under that plan. Rights surrendered to us were 4,461 and 16,915 shares valued at $47 thousand and $211 thousand for the three and nine months ended September 30, 2025, respectively. Such shares of common stock, unless canceled, may be reissued for a variety of purposes such as future acquisitions, non-employee director stock awards or employee stock awards.

Dividend Policy

In March, May and August 2025, we paid a quarterly cash dividend of $0.01 per share of common stock. In addition, on October 22, 2025, we declared a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on November 3, 2025, and payable on November 24, 2025.

Accumulated Other Comprehensive Income (Loss)

Amounts recognized, net of income tax, in accumulated other comprehensive income (loss) consist of the following (in thousands):

15

Return to Index

		September 30, 2025				December 31, 2024
Pension and other post-retirement benefit plans - unrecognized prior service costs and net actuarial loss		$	(5,719	)		$	(5,890	)
Interest rate swaps - net gain (loss) on fair value			(265	)			121
Total accumulated other comprehensive income (loss)		$	(5,984	)		$	(5,769	)

11. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We are exposed to market risks related to fluctuations in interest rates. To mitigate these risks, we may utilize derivative instruments in the form of interest rate swaps. We do not enter into derivative transactions for speculative purposes.

In March 2021, we entered into a forward interest rate swap agreement and carried the fair value of certain terminated variable-to-fixed swaps into the agreement in a “blend and extend” structured transaction. The purpose of this forward interest rate swap agreement is to fix the underlying risk-free rate, that would be associated with the anticipated issuance of new long-term debt by the Company in future periods. The forward interest rate swap would hedge the risk-free rate on forecasted long-term debt through March 2033. Risk associated with future changes in the 10-year LIBOR interest rates have been fixed up to a notional amount of $60.0 million with this instrument. The interest rate swap qualifies as a cash flow hedging instrument. This forward interest rate swap agreement was terminated and settled in April 2022. The hedging relationship is highly effective, therefore, the gain on the termination of the forward interest rate swap was included in accumulated other comprehensive income (loss). On June 28, 2023, the Company issued the 2023 Senior Notes in the aggregate principal amount of $50.0 million at fixed interest rates of 7.25% and 7.50%. The Company has elected to apply the optional expedient for hedging relationships affected by reference rate reform. Accordingly, no outstanding balance on the 2023 Senior Notes will preclude cash flow hedging with the existing LIBOR hedging instrument. A net loss of $0.3 million is included in accumulated other comprehensive income (loss) at September 30, 2025. The unamortized balance on this swap will be amortized into interest expense in accordance with the forecasted transactions or the scheduled interest payments on the 2023 Senior Notes and any future debt through March 2033.

The effect of interest rate swaps on the consolidated statements of operations is as follows (in thousands):

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024				Income Statement Classification
Derivatives designated as hedges:
5 year interest rate swap		$	—			$	5			$	(12	)		$	67			Increase (decrease) to interest expense
10 year interest rate swap			(108	)			(240	)			(477	)			(847	)		Increase (decrease) to interest expense
		$	(108	)		$	(235	)		$	(489	)		$	(780	)

12. FINANCIAL INSTRUMENTS

The Company’s only financial assets and liabilities which are measured at fair value on a recurring basis relate to certain aspects of the Company’s benefit plans. We use the market approach to determine the fair value of these assets and liabilities using significant other observable inputs (Level 2) with the assistance of third-party specialists. We do not have any assets or liabilities measured at fair value on a recurring basis using quoted prices in an active market (Level 1) or significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the financial assets and liabilities are recorded in general and administrative expense in the consolidated statements of operations.

16

Return to Index

The following table summarizes the fair value balances (in thousands):

						Fair Value Measurement at
						September 30, 2025
		Total				Level 1				Level 2				Level 3
Assets:
Company owned life insurance policies (1)		$	26,518			$	—			$	26,518			$	—
		$	26,518			$	—			$	26,518			$	—
Liabilities:
Deferred compensation liabilities		$	20,536			$	—			$	20,536			$	—
		$	20,536			$	—			$	20,536			$	—

						Fair Value Measurement at
						December 31, 2024
		Total				Level 1				Level 2				Level 3
Assets:
Company owned life insurance policies (1)		$	25,435			$	—			$	25,435			$	—
		$	25,435			$	—			$	25,435			$	—
Liabilities:
Deferred compensation liabilities		$	19,103			$	—			$	19,103			$	—
		$	19,103			$	—			$	19,103			$	—

(1) Company owned life insurance policies have cash surrender value and are intended to assist in funding deferred compensation liabilities and other benefit plans.

13. OTHER (INCOME) EXPENSE, NET

The components of other (income) expense, net, are as follows (in thousands):

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
(Gain) loss on sale of assets		$	(146	)		$	364			$	(369	)		$	(390	)
Results of non-consolidated subsidiaries			194				(108	)			401				(207	)
Foreign exchange (gain) loss, net			354				(239	)			841				435
Rents and royalties			(8	)			(882	)			(24	)			(1,683	)
Return on pension assets and other pension costs			(312	)			(314	)			(893	)			(891	)
Assets write-down, loss on lease abandonment and other exit costs			—				—				707				1,809
Insurance recovery - business interruption and costs			(52	)			(1,151	)			(1,031	)			(3,481	)
Insurance recovery - property, plant and equipment			(5,253	)			(2,074	)			(6,830	)			(2,074	)
Severance and other charges			—				—				2,256				824
Other, net			(367	)			(125	)			(1,280	)			(415	)
Total other (income) expense, net		$	(5,590	)		$	(4,529	)		$	(6,222	)		$	(6,073	)

During the nine months ended September 30, 2025 and 2024, as a result of consolidating and exiting certain facilities in the U.S. and other international locations, we recognized a write-down of the associated leasehold improvements, right of use assets and other assets and incurred lease abandonment and other exit costs of $0.7 million and $1.8 million, respectively.

In February 2024, we had a fire incident at our Aberdeen, U.K. facility and we have recorded insurance recovery associated with business interruptions, increase in cost of work, and loss on property and assets during the three and nine months ended September 30, 2025 and 2024. During the three months ended September 30, 2025, Core Lab reached final settlement with the insurance company and recorded a gain of approximately $5.2 million on the insurance recovery.

17

Return to Index

Foreign exchange (gain) loss, net by currency is summarized in the following table (in thousands):

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
British Pound		$	(48	)		$	(64	)		$	(108	)		$	6
Canadian Dollar			43				(13	)			(11	)			60
Colombian Peso			(38	)			44				(98	)			13
Euro			(30	)			201				772				266
Indonesian Rupiah			100				(332	)			133				(107	)
Russian Ruble			144				(4	)			(189	)			10
Swedish Krona			5				23				128				(7	)
Other currencies, net			178				(94	)			214				194
Foreign exchange (gain) loss, net		$	354			$	(239	)		$	841			$	435

14. INCOME TAX EXPENSE (BENEFIT)

The Company recorded an income tax expense of $3.8 million and $7.4 million for the three and nine months ended September 30, 2025, respectively compared to income tax expense of $4.7 million and $10.0 million for the three and nine months ended September 30, 2024, respectively. The effective tax rate for the three and nine months ended September 30, 2025, was 20.5% and 22.7%, respectively. The effective tax rate for the three and nine months ended September 30, 2024, was 28.1% and 28.8%, respectively. The effective tax rate for the three and nine months ended September 30, 2025, was primarily impacted by the earnings mix of jurisdictions subject to tax for the period and changes in uncertain tax position in certain jurisdictions which is discrete to the quarter. The tax rate for the three and nine months ended September 30, 2024 was impacted by the earnings mix of jurisdictions subject to tax for the period and items discrete to the quarter.

On July 4, 2025, the “One Big Beautiful Bill Act” (the “Act”) was enacted into law. The Act includes significant provisions, including tax cut extensions and modifications to the U.S. and international tax frameworks. We are evaluating the impact of these legislative changes as additional guidance becomes available. Currently, we do not believe legislation will have a material impact on our tax expense.

15. EARNINGS PER SHARE

We compute basic earnings per share by dividing net income attributable to Core Laboratories Inc. by the number of weighted average common shares outstanding during the period. Diluted earnings per share includes the incremental effect of contingently issuable shares from performance and restricted stock awards, as determined using the treasury stock method.

The following table summarizes the calculation of weighted average common shares outstanding used in the computation of basic and diluted earnings per share (in thousands):

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
Weighted average common shares outstanding - basic			46,263				46,922				46,552				46,897
Effect of dilutive securities:
Restricted shares			31				108				39				76
Performance shares			784				790				790				717
Weighted average common shares outstanding - diluted			47,078				47,820				47,381				47,690

18

Return to Index

16. SEGMENT REPORTING

We operate our business in two segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields.

• Reservoir Description: Encompasses the characterization of petroleum reservoir rock and reservoir fluids samples to increase production and improve recovery of crude oil and natural gas from our clients’ reservoirs. We provide laboratory-based analytical and field services to characterize properties of crude oil and crude oil-derived products to the oil and gas industry. Services associated with these fluids include determining the quality and measuring the quantity of the reservoir fluids and their derived products, such as gasoline, diesel and biofuels. We also provide proprietary and joint industry studies based on these types of analyses and manufacture associated laboratory equipment. In addition, we provide reservoir description capabilities that support various activities associated with energy transition projects, including services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities around lithium and other elements necessary for energy storage.

• Production Enhancement: Includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. We provide integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

We use the same accounting policies to prepare our operating segment results as are used to prepare our consolidated financial statements. All interest and other non-operating income (expense) is attributable to Corporate & Other and is not allocated to specific operating segments.

Our chief operating decision maker (“CODM”) is our Chief Executive Officer, who also serves as Chairman of the Board of Directors. The CODM uses revenue from unaffiliated clients and segment operating income to allocate resources, primarily for working capital, staffing and capital expenditures, during the annual budgeting process and monthly when comparing actual results to budgeted and forecasted results.

Summarized financial information of our operating segments is shown in the following table (in thousands):

19

Return to Index

		Reservoir Description				Production Enhancement				Corporate & Other (1)				Consolidated
Three months ended September 30, 2025
CODM Measure - Revenue from unaffiliated clients		$	88,224			$	46,297			$	—			$	134,521
Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income:
Inter-segment revenue			79				41				(120	)			—
Cost of services and product sales			67,156				37,553				192				104,901
General and administrative expense (2)			6,900				3,788				—				10,688
Depreciation and amortization			2,594				1,000				—				3,594
Other operating (income) expense, net (3)			(5,232	)			(306	)			(406	)			(5,944	)
Foreign exchange (gain) loss, net (3)			311				(76	)			119				354
CODM Measure - Segment operating income			16,574				4,379				(25	)			20,928
Supplemental Disclosures:
Total assets			322,047				143,219				126,094				591,360
Capital expenditures			2,706				183				142				3,031
Three months ended September 30, 2024
CODM Measure - Revenue from unaffiliated clients		$	88,840			$	45,557			$	—			$	134,397
Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income:
Inter-segment revenue			34				125				(159	)			—
Cost of services and product sales			68,544				38,490				(229	)			106,805
General and administrative expense (2)			5,542				3,100				—				8,642
Depreciation and amortization			2,618				1,058				—				3,676
Other operating (income) expense, net (3)			(4,160	)			(81	)			(49	)			(4,290	)
Foreign exchange (gain) loss, net (3)			(157	)			(117	)			35				(239	)
CODM Measure - Segment operating income			16,487				3,232				84				19,803
Supplemental Disclosures:
Total assets			322,001				154,995				123,470				600,466
Capital expenditures			2,273				427				29				2,729
Nine months ended September 30, 2025
CODM Measure - Revenue from unaffiliated clients		$	255,401			$	132,864			$	—			$	388,265
Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income:
Inter-segment revenue			136				155				(291	)			—
Cost of services and product sales			198,701				108,690				680				308,071
General and administrative expense (2)			22,754				12,045				—				34,799
Depreciation and amortization			7,854				3,127				—				10,981
Other operating (income) expense, net (3)			(5,576	)			143				(1,630	)			(7,063	)
Foreign exchange (gain) loss, net (3)			688				(16	)			169				841
CODM Measure - Segment operating income			31,116				9,030				490				40,636
Supplemental Disclosures:
Total assets			322,047				143,219				126,094				591,360
Capital expenditures			8,880				1,887				170				10,937
Nine months ended September 30, 2024
CODM Measure - Revenue from unaffiliated clients		$	259,353			$	135,258			$	—			$	394,611
Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income:
Inter-segment revenue			71				187				(258	)			—
Cost of services and product sales			201,989				112,207				127				314,323
General and administrative expense (2)			19,842				10,848				—				30,690
Depreciation and amortization			8,089				3,200				—				11,289
Other operating (income) expense, net (3)			(5,753	)			(55	)			(700	)			(6,508	)
Foreign exchange (gain) loss, net (3)			434				36				(35	)			435
CODM Measure - Segment operating income			34,823				9,209				350				44,382
Supplemental Disclosures:
Total assets			322,001				154,995				123,470				600,466
Capital expenditures			7,481				914				252				8,647

(1) "Corporate & Other" represents those items that are not directly related to a particular operating segment and eliminations.

(2) General and administrative expense is presented as a total amount to the CODM and consists primarily of employee compensation costs, professional fees and information technology costs.

(3) Other remaining balance is included in other (income) expense, net. See Note 13 - Other (income) expense, net for further details.

20

Return to Index

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion highlights the current operating environment and summarizes the financial position of Core Laboratories Inc. and its subsidiaries as of September 30, 2025, and should be read in conjunction with (i) the unaudited interim consolidated financial statements and notes thereto included elsewhere in this Quarterly Report and (ii) the audited consolidated financial statements and accompanying notes thereto included in our 2024 Annual Report on Form 10-K for the year ended December 31, 2024.

General

Core Laboratories Inc. is a Delaware corporation. It was established in 1936 and is one of the world's leading providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry. These services and products can enable our clients to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. We make measurements on reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. In addition, we assist clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Core Laboratories Inc. has over 70 offices in more than 50 countries and employs approximately 3,300 people worldwide.

References to “Core Lab”, “Core Laboratories”, the “Company”, “we”, “our” and similar phrases are used throughout this Quarterly Report and relate collectively to Core Laboratories Inc. and its consolidated affiliates.

We operate our business in two segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields.

• Reservoir Description: Encompasses the characterization of petroleum reservoir rock and reservoir fluids samples to increase production and improve recovery of crude oil and natural gas from our clients' reservoirs. We provide laboratory-based analytical and field services to characterize properties of crude oil and crude oil-derived products to the oil and gas industry. Services associated with these fluids include determining the quality and measuring the quantity of the reservoir fluids and their derived products, such as gasoline, diesel and biofuels. We also provide proprietary and joint industry studies based on these types of analyses and manufacture associated laboratory equipment. In addition, we provide reservoir description capabilities that support various activities associated with energy transition projects, including services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities around lithium and other elements necessary for energy storage.

• Production Enhancement: Includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. We provide integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (“Exchange Act”). Certain statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations section, including those under the headings “Outlook” and “Liquidity and Capital Resources”, and in other parts of this Quarterly Report, are forward-looking. In addition, from time to time, we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. Forward-looking statements can be identified by the use of forward-looking terminology such as “may”, “will”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, or other similar words, including statements as to the intent, belief, or current expectations of our directors, officers, and management with respect to our future operations, performance, or positions or

21

Return to Index

which contain other forward-looking information. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. While management believes that these forward-looking statements are reasonable as and when made, no assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While we believe that these statements are and will be accurate, our actual results and experience may differ materially from the anticipated results or other expectations expressed in our statements due to a variety of risks and uncertainties.

We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of some of the foregoing risks and uncertainties, see Part II, “Item 1A - Risk Factors” of this Quarterly Report and “Item 1A - Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2024, filed by us with the Securities and Exchange Commission (“SEC”).

Outlook

According to the latest reports from the U.S. Energy Information Administration, the International Energy Agency (“IEA”) and the Organization of the Petroleum Exporting Countries and other oil producing nations (“OPEC+”), global demand for crude oil and natural gas is expected to continue increasing in 2025 and beyond. New tariffs announced by the U.S. during the year have triggered global trade negotiations and have raised the level of uncertainty for global economies. Additionally, OPEC+ affirmed their decision to proceed with a gradual return of 2.2 million barrels of daily production by removing the voluntary production restrictions established in 2023. The gradual increase in production from OPEC+ began in May 2025 with incremental increases in production expected through September 2026, which could create a surplus in supply and lead to lower commodity prices. OPEC also published an updated “compensation plan” which shows committed reductions in production for countries that produced volumes over their committed quotas since January 2024, which if complied with, should partially offset the scheduled increases to production quotas. In each announcement from OPEC+ regarding the production increases, they have also stated they will continue to hold monthly meetings to review market conditions, conformity, and compensation.

The uncertainty around the impact global trade negotiations may have on global economies combined with OPEC+’s announcement of increased production quotas has also increased the likelihood that global inventory levels of crude oil will rise, thereby contributing to weaker crude oil prices. The Company believes that activity levels associated with smaller-scale, short-cycle crude oil development projects will be more sensitive to a decrease and/or continued volatility of crude-oil prices. As such, we expect changes in crude oil prices will have a greater impact on drilling and completion activity levels in the U.S. onshore market. Outside the U.S., large-scale international oil and gas projects are expected to be more resilient to the near-term volatility of crude-oil prices, and the Company anticipates current client projects to continue as planned and additional projects scheduled this year to also be executed as planned. Recently, revised IEA field data showed that a steeper natural decline rate may represent a dominant long-term supply risk, where the agency projected a sustained upstream investment of approximately $540 to $570 billion per year is required to prevent disruptive declines and to avoid price volatility.

The ongoing geopolitical conflicts between Russia and Ukraine and in the Middle East, along with associated and expanded sanctions in the United States, the European Union, the United Kingdom and other countries continue to cause disruptions to traditional maritime supply chains and the trading of crude oil and derived products, such as diesel fuel. These disruptions to the trading and maritime transportation of crude oil, also impact the demand for the Company's associated laboratory assay services. Although demand for the Company’s laboratory assay analysis services continued to increase during the first nine months of 2025, these geopolitical conflicts and associated sanctions continue to create a higher level of uncertainty. We have no way to predict the progress or outcome of these events, and any resulting government responses are fluid and beyond our control.

We continue to focus on large-scale core analyses and reservoir fluids characterization studies in most oil-producing regions across the globe, which include both newly developed fields and brownfield extensions in many offshore developments in both the U.S. and internationally. In the U.S., we are involved in projects with many of the onshore unconventional basins, as well as

22

Return to Index

offshore projects in the Gulf of Mexico. Outside the U.S., we continue to work on many small and large-scale projects analyzing reservoir rock and fluid samples in every major producing region of the world. Notable larger projects are in locations such as offshore South America, Australia, West Africa and the Middle East. Analysis and measurement services also occur in every major producing region of the world. Additionally, some of our major clients have increased their investment in projects to capture and sequester carbon dioxide in recent years that has expanded the Company’s activities on these projects beginning in 2024 and into 2025.

Our major clients continue to focus on capital management, return on invested capital, free cash flow and returning capital to their shareholders, as opposed to a focus on production growth. The companies adopting value versus volume metrics tend to be the more technologically sophisticated operators and form the foundation of Core Lab’s worldwide client base. As oil and gas commodity prices stabilize in the mid-to-long-term, the Company expects our clients’ activities associated with increasing oil and gas reserves and production levels will continue to increase in the coming years.

23

Return to Index

Results of Operations

Our results of operations as a percentage of applicable revenue are as follows (in thousands):

		Three Months Ended September 30,
		2025						2024						$ Change				% Change
REVENUE:
Services		$	101,125			75%		$	98,842			74%		$	2,283			2%
Product sales			33,396			25%			35,555			26%			(2,159	)		(6)%
Total revenue			134,521			100%			134,397			100%			124			0%
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below*			74,896			74%			75,503			76%			(607	)		(1)%
Cost of product sales, exclusive of depreciation expense shown below*			30,005			90%			31,302			88%			(1,297	)		(4)%
Total cost of services and product sales			104,901			78%			106,805			79%			(1,904	)		(2)%
General and administrative expense, exclusive of depreciation expense shown below			10,688			8%			8,642			6%			2,046			24%
Depreciation and amortization			3,594			3%			3,676			3%			(82	)		(2)%
Other (income) expense, net			(5,590	)		(4)%			(4,529	)		(3)%			(1,061	)		23%
OPERATING INCOME			20,928			16%			19,803			15%			1,125			6%
Interest expense			2,650			2%			3,108			2%			(458	)		(15)%
Income before income taxes			18,278			14%			16,695			12%			1,583			9%
Income tax expense			3,754			3%			4,691			3%			(937	)		(20)%
Net income			14,524			11%			12,004			9%			2,520			21%
Net income attributable to non-controlling interest			285			—%			259			—%			26			NM
Net income attributable to Core Laboratories Inc.		$	14,239			11%		$	11,745			9%		$	2,494			21%
Other Data:
Current ratio (1)		2.37:1						2.48:1
Debt to EBITDA ratio (2)		1.18:1						1.58:1
Debt to Adjusted EBITDA ratio (3)		1.10:1						1.47:1

“NM” means not meaningful

*Percentage based on applicable revenue rather than total revenue

(1)Current ratio is calculated as follows: current assets divided by current liabilities.

(2)Debt to EBITDA ratio is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization and certain non-cash adjustments.

(3)Debt to Adjusted EBITDA ratio (as defined in our Credit Facility) is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization, impairments, severance and certain non-cash adjustments.

24

Return to Index

		Three Months Ended
		September 30, 2025						June 30, 2025						$ Change				% Change
REVENUE:
Services		$	101,125			75%		$	96,219			74%		$	4,906			5%
Product sales			33,396			25%			33,940			26%			(544	)		(2)%
Total revenue			134,521			100%			130,159			100%			4,362			3%
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below*			74,896			74%			74,053			77%			843			1%
Cost of product sales, exclusive of depreciation expense shown below*			30,005			90%			29,648			87%			357			1%
Total cost of services and product sales			104,901			78%			103,701			80%			1,200			1%
General and administrative expense, exclusive of depreciation expense shown below			10,688			8%			10,464			8%			224			2%
Depreciation and amortization			3,594			3%			3,670			3%			(76	)		(2)%
Other (income) expense, net			(5,590	)		(4)%			(2,967	)		(2)%			(2,623	)		88%
OPERATING INCOME			20,928			16%			15,291			12%			5,637			37%
Interest expense			2,650			2%			2,711			2%			(61	)		(2)%
Income before income taxes			18,278			14%			12,580			10%			5,698			45%
Income tax expense			3,754			3%			1,911			1%			1,843			96%
Net income			14,524			11%			10,669			8%			3,855			36%
Net income attributable to non-controlling interest			285			—%			33			—%			252			NM
Net income attributable to Core Laboratories Inc.		$	14,239			11%		$	10,636			8%		$	3,603			34%
Other Data:
Current ratio (1)		2.37:1						2.27:1
Debt to EBITDA ratio (2)		1.18:1						1.33:1
Debt to Adjusted EBITDA ratio (3)		1.10:1						1.27:1

“NM” means not meaningful

*Percentage based on applicable revenue rather than total revenue

(1)Current ratio is calculated as follows: current assets divided by current liabilities.

(2)Debt to EBITDA ratio is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation and amortization and certain non-cash adjustments.

(3)Debt to Adjusted EBITDA ratio (as defined in our Credit Facility) is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization, impairments, severance and certain non-cash adjustments.

25

Return to Index

		Nine Months Ended September 30,
		2025						2024						$ Change				% Change
REVENUE:
Services		$	292,435			75%		$	291,674			74%		$	761			0%
Product sales			95,830			25%			102,937			26%			(7,107	)		(7)%
Total revenue			388,265			100%			394,611			100%			(6,346	)		(2)%
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below*			221,929			76%			224,191			77%			(2,262	)		(1)%
Cost of product sales, exclusive of depreciation expense shown below*			86,142			90%			90,132			88%			(3,990	)		(4)%
Total cost of services and product sales			308,071			79%			314,323			80%			(6,252	)		(2)%
General and administrative expense, exclusive of depreciation expense shown below			34,799			9%			30,690			8%			4,109			13%
Depreciation and amortization			10,981			3%			11,289			3%			(308	)		(3)%
Other (income) expense, net			(6,222	)		(2)%			(6,073	)		(2)%			(149	)		2%
OPERATING INCOME			40,636			10%			44,382			11%			(3,746	)		(8)%
Interest expense			7,963			2%			9,740			2%			(1,777	)		(18)%
Income before income taxes			32,673			8%			34,642			9%			(1,969	)		(6)%
Income tax expense			7,411			2%			9,958			3%			(2,547	)		(26)%
Net income			25,262			7%			24,684			6%			578			2%
Net income attributable to non-controlling interest			541			—%			687			—%			(146	)		NM
Net income attributable to Core Laboratories Inc.		$	24,721			6%		$	23,997			6%		$	724			3%
Other Data:
Current ratio (1)		2.37:1						2.48:1
Debt to EBITDA ratio (2)		1.18:1						1.58:1
Debt to Adjusted EBITDA ratio (3)		1.10:1						1.47:1

“NM” means not meaningful

*Percentage based on applicable revenue rather than total revenue

(1)Current ratio is calculated as follows: current assets divided by current liabilities.

(2)Debt to EBITDA ratio is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation and amortization and certain non-cash adjustments.

(3)Debt to Adjusted EBITDA ratio (as defined in our Credit Facility) is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization, impairments, severance and certain non-cash adjustments.

Operating Results for the Three Months Ended September 30, 2025 compared to the Three Months Ended September 30, 2024 and June 30, 2025 and for the Nine Months Ended September 30, 2025 compared to the Nine Months Ended September 30, 2024

Service Revenue

Service revenue is primarily tied to activities associated with the exploration, appraisal, development and production of oil, gas and derived products outside the U.S. For the three months ended September 30, 2025, service revenue was $101.1 million, an increase of 2% year-over-year and an increase of 5% sequentially. Year-over-year, revenues increased primarily due to the increase in international markets partially offset by lower activity level in the U.S. market. Despite disruptions from the ongoing geopolitical conflicts and expanded sanctions throughout the first nine months of 2025, we continue to see recovery in demand for our laboratory crude-assay services during the third quarter of 2025 and continued growth in well completion diagnostic services in certain international markets when compared to the same period in 2024. Service revenue in 2025 has

26

Return to Index

been negatively impacted by certain projects that were planned and scheduled but were canceled, as the wells drilled by our clients were determined to be uneconomical or unsuccessful.

Sequentially, the increase in service revenue was primarily due to an increase in demand for laboratory crude-assay services in international markets while the U.S. market remained relatively flat. As discussed above, the expanded sanctions imposed throughout the year have caused a temporary disruption in the trading and maritime transportation of crude oil and derived products that slowed the growth of laboratory crude-assay revenue during 2025.

For the nine months ended September 30, 2025, service revenue was $292.4 million, relatively flat compared to the same period in the prior year. Year-over-year, the demand for laboratory crude-assay services and well completion diagnostic services continued to grow in the international markets. Additionally, reservoir rock and fluid analysis services have been negatively impacted due to the decline in international offshore commercial success rates for exploration and appraisal well projects, as discussed above.

Product Sales Revenue

Product sales are primarily tied to U.S. onshore drilling and completion activities and product sales to international markets. Product sales to international markets are typically sold and shipped in bulk, and revenue can vary from one quarter to another. For the three months ended September 30, 2025, product sales revenue of $33.4 million decreased 6% year-over-year and 2% sequentially. The decrease was driven by lower drilling and completion activity onshore in the U.S. for the three months ended September 30, 2025 when compared to the same period in 2024.

Sequentially, the slight decrease was due to the lower level of U.S. onshore drilling and completion activity but was substantially offset by higher levels of bulk shipments to international markets.

For the nine months ended September 30, 2025, product sales revenue was $95.8 million and decreased 7% compared to the same period in the prior year, primarily due to lower average U.S. onshore drilling and completion activity in 2025 compared to 2024, but was partially offset by an increase of laboratory instrument sales to international markets in 2025.

Cost of Services, excluding depreciation

Cost of services was $74.9 million for the three months ended September 30, 2025, a decrease of 1% year-over-year and an increase of 1% sequentially. The year-over-year decrease in cost of services was primarily due to increased efficiencies and the benefits of lower compensation costs as a result of cost reduction initiatives implemented during the first half of 2025. Sequentially, the slight increase in cost of services is primarily due to an increase in service revenue partially offset by the increased efficiencies and lower compensation cost as discussed above. Cost of services expressed as a percentage of service revenue was 74% for the three months ended September 30, 2025, compared to 77% for the prior quarter and 76% for the same period in the prior year. Cost of services as a percentage of service revenue improved primarily driven by the efficiencies and cost reduction initiatives as discussed above.

For the nine months ended September 30, 2025, cost of services was $221.9 million, a decrease of 1% compared to the same period in the prior year. Cost of services expressed as a percentage of service revenue improved to 76% from 77% when compared to the same period in the prior year. The year-over-year decrease in cost of services while service revenue remained relatively flat was primarily due to increased efficiencies and cost reduction initiatives as discussed above.

Cost of Product Sales, excluding depreciation

Cost of product sales was $30.0 million for the three months ended September 30, 2025, a decrease of 4% year-over-year and an increase of 1% sequentially. Cost of product sales expressed as a percentage of product sales revenue was 90% for the three months ended September 30, 2025, compared to 88% for the same period in the prior year and compared to 87% in the prior quarter. The year-over-year changes in cost of product sales as a percentage of product sales increased primarily due to higher absorption of fixed costs on a lower revenue base that is partially associated with increased tariff cost on certain imported

27

Return to Index

materials, along with a write-down of certain inventory of approximately $0.6 million in the three months ended September 30, 2025.

Sequentially, cost of product sales as a percentage of product sales increased due to higher absorption of fixed costs on a lower revenue base.

For the nine months ended September 30, 2025, cost of product sales was $86.2 million, a decrease of 4% compared to the same period in the prior year. Cost of product sales expressed as a percentage of product sales revenue was 90% for the nine months ended September 30, 2025, compared to 88% from the same period in the prior year. The increase in cost of product sales as a percentage of product sales revenue was due to higher absorption of fixed costs on a lower revenue base as discussed above, along with a write-down of certain inventory totaled $1.8 million in 2025, with no such write-down in the same period in the prior year.

General and Administrative Expense, excluding depreciation

General and administrative (“G&A”) expense includes corporate management and centralized administrative services that benefit our operations.

G&A expense for the three months ended September 30, 2025, was $10.7 million, which increased $2.0 million, compared to the same period in 2024. The year-over-year increase was primarily due to higher stock compensation expense recorded in 2025. In 2024, a portion of stock compensation expense that was previously recognized was reversed to align with the expectations of vesting levels for certain performance share awards.

G&A expense for the three months ended September 30, 2025, was comparable to the prior quarter and increased $0.2 million or less than 2%.

For the nine months ended September 30, 2025, G&A expense was $34.8 million which increased $4.1 million, compared to the nine months ended September 30, 2024. The year-over-year increase was primarily due to (1) a higher total stock compensation cost of $1.8 million; (2) a lower gain from mark-to-market adjustments on Company-owned life insurance policies of $1.3 million; and (3) increased license fees and implementation costs associated with a new global human capital management system.

Depreciation and Amortization Expense

Depreciation and amortization expense for the three months ended September 30, 2025, was $3.6 million, a decrease of 2% year-over-year and sequentially. Depreciation and amortization expense for the nine months ended September 30, 2025, was $11.0 million, a decrease of 3% year-over-year. The decrease in depreciation and amortization expense compared to the prior year periods and sequentially is primarily due to assets that had become fully depreciated.

28

Return to Index

Other (Income) Expense, Net

The components of other (income) expense, net, are as follows (in thousands):

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
(Gain) loss on sale of assets		$	(146	)		$	364			$	(369	)		$	(390	)
Results of non-consolidated subsidiaries			194				(108	)			401				(207	)
Foreign exchange (gain) loss, net			354				(239	)			841				435
Rents and royalties			(8	)			(882	)			(24	)			(1,683	)
Return on pension assets and other pension costs			(312	)			(314	)			(893	)			(891	)
Assets write-down, loss on lease abandonment and other exit costs			—				—				707				1,809
Insurance recovery - business interruption and costs			(52	)			(1,151	)			(1,031	)			(3,481	)
Insurance recovery - property, plant and equipment			(5,253	)			(2,074	)			(6,830	)			(2,074	)
Severance and other charges			—				—				2,256				824
Other, net			(367	)			(125	)			(1,280	)			(415	)
Total other (income) expense, net		$	(5,590	)		$	(4,529	)		$	(6,222	)		$	(6,073	)

During the nine months ended September 30, 2025 and 2024, as a result of consolidating and exiting certain facilities in the U.S. and other international locations, we recognized a write-down of the associated leasehold improvements, right of use assets and other assets and incurred lease abandonment and other exit costs of $0.7 million and $1.8 million, respectively.

In February 2024, we had a fire incident at our Aberdeen, U.K. facility and we have recorded insurance recovery associated with business interruptions, increase in cost of work, and loss on property and assets during the three and nine months ended September 30, 2025 and 2024. During the three months ended September 30, 2025, Core Lab reached final settlement with the insurance company and recorded a gain of approximately $5.3 million on the insurance recovery.

Foreign exchange (gain) loss, net by currency is summarized in the following table (in thousands):

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
British Pound		$	(48	)		$	(64	)		$	(108	)		$	6
Canadian Dollar			43				(13	)			(11	)			60
Colombian Peso			(38	)			44				(98	)			13
Euro			(30	)			201				772				266
Indonesian Rupiah			100				(332	)			133				(107	)
Russian Ruble			144				(4	)			(189	)			10
Swedish Krona			5				23				128				(7	)
Other currencies, net			178				(94	)			214				194
Foreign exchange (gain) loss, net		$	354			$	(239	)		$	841			$	435

Interest Expense

Interest expense for the three months ended September 30, 2025, was $2.7 million and decreased $0.5 million or 15% year-over-year and 2% compared to the prior quarter. For the nine months ended September 30, 2025, interest expense decreased $1.8 million or 18%.

The year-over-year and sequential decreases are primarily due to lower variable interest rates and average borrowings on our bank revolving credit facility during the three and nine months ended September 30, 2025.

29

Return to Index

Income Tax Expense (Benefit)

The Company recorded an income tax expense of $3.8 million and $7.4 million for the three and nine months ended September 30, 2025, respectively compared to income tax expense of $4.7 million and $10.0 million for the three and nine months ended September 30, 2024, respectively. The effective tax rate for the three and nine months ended September 30, 2025, was 20.5% and 22.7%, respectively. The effective tax rate for the three and nine months ended September 30, 2024, was 28.1% and 28.8%, respectively. The effective tax rate for the three and nine months ended September 30, 2025, was primarily impacted by the earnings mix of jurisdictions subject to tax for the period and changes in uncertain tax position in certain jurisdictions which is discrete to the quarter. The tax rate for the three and nine months ended September 30, 2024 was impacted by the earnings mix of jurisdictions subject to tax for the period and items discrete to the quarter.

On July 4, 2025, the Act was enacted into law. The Act includes significant provisions, including tax cut extensions and modifications to the U.S. and international tax frameworks. We are evaluating the impact of these legislative changes as additional guidance becomes available, and uncertainty remains regarding the timing and interpretation by tax authorities in affected jurisdictions. These legislative changes could have an adverse impact on our future effective tax rate, tax assets and liabilities, including our deferred tax assets and liabilities, and cash payments for tax.

Segment Analysis

We operate our business in two segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. The following tables summarize our results by operating segment (in thousands):

		Three Months Ended																		Year-over-year		Sequential
		September 30, 2025						September 30, 2024						June 30, 2025						%Change		%Change
REVENUE:
Reservoir Description		$	88,224			66%		$	88,840			66%		$	86,280			66%		(1)%		2%
Production Enhancement			46,297			34%			45,557			34%			43,879			34%		2%		6%
Consolidated		$	134,521			100%		$	134,397			100%		$	130,159			100%		0%		3%
OPERATING INCOME:
Reservoir Description *		$	16,574			19%		$	16,487			19%		$	12,203			14%		1%		36%
Production Enhancement *			4,379			9%			3,232			7%			3,148			7%		35%		39%
Corporate and Other (1)			(25	)		0%			84			0%			(60	)		0%		NM		NM
Consolidated		$	20,928			16%		$	19,803			15%		$	15,291			12%		6%		37%
* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue. "NM" means not meaningful (1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.

		Nine Months Ended September 30,												Year-over-year
		2025						2024						% Change
REVENUE:
Reservoir Description		$	255,401			66%		$	259,353			66%		(2)%
Production Enhancement			132,864			34%			135,258			34%		(2)%
Consolidated		$	388,265			100%		$	394,611			100%		(2)%
OPERATING INCOME (LOSS):
Reservoir Description *		$	31,116			12%		$	34,823			13%		(11)%
Production Enhancement *			9,030			7%			9,209			7%		(2)%
Corporate and Other (1)			490			0%			350			0%		NM
Consolidated		$	40,636			10%		$	44,382			11%		(8)%
* Percentage, which represents operating margin, is based on operating income divided by applicable revenue rather than total revenue. "NM" means not meaningful (1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.

30

Return to Index

Reservoir Description

Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of its revenue sourced from existing producing fields, development projects and movement of crude oil products outside the U.S.

Revenue from the Reservoir Description operating segment of $88.2 million for the three months ended September 30, 2025 decreased 1% year-over-year and increased 2% sequentially. Revenue in 2025 has been negatively impacted by the decrease in the success rate for international offshore exploration and appraisal wells, which reached a 20-year low for the six-month period ending March 31, 2025. The decrease in international offshore commercial success rates has resulted in the cancellation of several reservoir rock and fluid analysis projects that were originally planned for late 2024 and 2025. The slight decrease in year-over-year revenue was primarily due to lower revenue in reservoir rock and fluid analysis projects in the U.S. but was substantially offset by higher revenue from international projects and crude-assay services. Sequentially, the increase in revenue was primarily due to higher revenue in laboratory crude-assay services.

Revenue from the Reservoir Description operating segment of $255.4 million for the nine months ended September 30, 2025 decreased 2% from the same period in the prior year. The decreased revenue in 2025 is primarily due to lower revenue in reservoir rock and fluid analysis in the U.S., as discussed above. The decrease is partially offset by higher revenue in international laboratory crude-assay services and higher laboratory instrument sales in 2025.

Operating income of $16.6 million for the three months ended September 30, 2025, was relatively flat year-over-year and increased $4.4 million sequentially. Operating margins were 19% for the three months ended September 30, 2025, comparable for the same period in the prior year, and 14% sequentially. Year-over-year, the changes in operating income and operating margins was primarily attributable to gains on insurance recovery associated with the fire at the Aberdeen, U.K. facility of $5.3 million recorded in the three months ended September 30, 2025, compared to a $3.2 million gain in the same period in prior year. The additional gain on insurance recovery was substantially offset by a different mix of revenue with a higher level of laboratory instrument sales in 2025, which yield a lower margin.

Sequentially, the increase in operating income and operating margins was primarily due to 1) incremental revenue of $2.0 million in the three months ended September 30, 2025; and 2) insurance recovery associated with the fire at the Aberdeen, U.K. facility of $5.3 million recorded in the three months ended September 30, 2025, compared to a $2.6 million recorded in the prior quarter.

Operating income of $31.1 million for the nine months ended September 30, 2025, decreased $3.7 million from the same period in the prior year. Operating margins were 12% for the nine months ended September 30, 2025, compared to 13% for the same period in the prior year. The decrease in operating income and operating margins was primarily attributable to 1) a lower level of revenue in 2025; 2) a different mix of revenue with a higher level of laboratory instrument sales that yield lower margin compared to service revenue; and 3) a total charge of $2.7 million associated with employee severance, facility consolidation and asset write-down recorded in 2025 compared to $1.5 million recorded in the same period in prior year. The decrease in operating income and operating margins was partially offset by a higher insurance recovery associated with the fire at the Aberdeen, U.K. facility in the nine months ended September 30, 2025, compared to the same period in prior year.

Production Enhancement

Production Enhancement operations are largely focused on complex completions in unconventional oil and gas reservoirs in the U.S. as well as conventional projects across the globe. U.S. onshore drilling and completion activities typically experience a seasonal decline at end of the year with activity levels increasing at the beginning of the year. Average rig count in the U.S. land market for the three months ended September 30, 2025, was down by 7% year-over-year and 6% sequentially. International rig count was down 6% year-over-year and relatively flat sequentially.

31

Return to Index

Revenue from the Production Enhancement operating segment of $46.3 million for the three months ended September 30, 2025, increased 2% year-over-year and 6% sequentially. Year-over-year, the increase was primarily driven by a strong growth in well completion diagnostic services in the U.S. and international markets. Sequentially, the increase was primarily driven by increased product sales in bulk shipment in the international markets, and continued growth in well completion diagnostic services for projects in the Gulf of Mexico.

Revenue from the Production Enhancement operating segment of $132.9 million for the nine months ended September 30, 2025, decreased 2% from the same period in the prior year. The decrease in revenue is primarily due to lower product sales in the U.S. land market in 2025, partially offset by higher revenue in well completion diagnostic services in the U.S. and international markets.

Operating income of $4.4 million for the three months ended September 30, 2025, increased $1.1 million year-over-year, and increased $1.2 million sequentially. Operating margins for the three months ended September 30, 2025, were 9%, compared to operating margins of 7% year-over-year and sequentially. Year-over-year, the increase in operating income and margins was primarily driven by a different mix of revenue with higher well completion diagnostic service revenue that yields a higher margin. Sequentially, the increase in operating income and margins was primarily driven by incremental revenue of $2.4 million in the three months ended September 30, 2025.

Operating income of $9.0 million for the nine months ended September 30, 2025, decreased $0.2 million compared to the same period in the prior year. Operating margins for the nine months ended September 30, 2025 of 7% were comparable to the same period of the prior year. The slight decrease in operating income and margins was primarily due to a higher absorption of fixed costs on lower product sales that is partially associated with increased tariff cost on certain imported materials, substantially offset by higher margin yield from well completion diagnostic service revenue as discussed above.

Liquidity and Capital Resources

General

We have historically financed our activities through cash on hand, cash flows from operations, bank credit facilities, equity financing and the issuance of debt. Cash flows from operating activities provide the primary source of funds to finance operating needs, capital expenditures, dividends and our share repurchase program. Our ability to maintain and grow our operating income and cash flow depends, to a large extent, on continued investing activities. We believe our future cash flows from operations, supplemented by our borrowing capacity and the ability to issue additional equity and debt, should be sufficient to fund our debt requirements, capital expenditures, working capital, dividends, share repurchase program and future acquisitions. The Company will continue to monitor and evaluate the availability of capital in the debt and equity markets.

We are a holding company incorporated in Delaware. Therefore, we conduct substantially all of our operations through our subsidiaries. Our cash availability is largely dependent upon the ability of our subsidiaries to pay cash dividends or otherwise distribute or advance funds to us and on the terms and conditions of our existing and future credit arrangements. There are no restrictions preventing any of our subsidiaries from repatriating earnings, except for the unrepatriated earnings of our Russian subsidiary which are not expected to be distributed in the foreseeable future, and there are no restrictions or income taxes associated with distributing cash to the parent company through loans or advances. As of September 30, 2025, $22.2 million of our $25.6 million of cash was held by our foreign subsidiaries.

The Company maintains the quarterly dividend of $0.01 per share.

Cash Flows

The following table summarizes cash flows (in thousands):

32

Return to Index

		Nine Months Ended September 30,
		2025				2024				% Change
Cash flows provided by (used in):
Operating activities		$	29,085			$	35,773			(19)%
Investing activities			1,521				(2,835	)		NM
Financing activities			(24,134	)			(26,584	)		(9)%
Net change in cash and cash equivalents		$	6,472			$	6,354			2%

Comparing the nine months ended September 30, 2025 to the same period in the prior year, cash flows provided by operating activities decreased to $29.1 million in 2025 compared to $35.8 million in 2024. Net income for the nine months ended September 30, 2025 includes gain on insurance proceeds associated with assets of $6.8 million compared to $2.1 million in the same period in the prior year. Additionally, cash from operating activities was impacted by a decrease in working capital in 2025 compared to the same period in the prior year.

Cash flows provided by investing activities for the nine months ended September 30, 2025 of $1.5 million include proceeds on the sale of assets of $2.4 million, proceeds from insurance recovery associated with the fire incident at the Aberdeen, U.K. facility of $10.0 million, and proceeds on company owned life insurance policies of $0.8 million, offset by total capital expenditures of $10.9 million and a business acquisition, net of cash acquired of $0.6 million. Cash flows used in investing activities for the nine months ended September 30, 2024 of $2.8 million include the funding of $8.6 million for capital expenditures, partially offset by $2.1 million of proceeds from insurance recovery associated with the 2024 fire incident, $0.9 million of proceeds from the sale of assets and $2.8 million of net proceeds received from company owned life insurance policies.

Cash flows used in financing activities for the nine months ended September 30, 2025 of $24.1 million include an $11.0 million net reduction in long-term debt, $1.7 million of debt issuance costs associated with the renewal of our credit facility, $1.4 million for quarterly dividends, and $9.8 million used to repurchase the Company’s common stock. Cash flows used in financing activities for the nine months ended September 30, 2024 of $26.6 million include a $24.0 million net reduction in long-term debt, $1.4 million for quarterly dividends, $0.4 million used to repurchase the Company’s common stock and $0.8 million in costs associated with equity transactions.

During the nine months ended September 30, 2025, we repurchased 831,478 shares of our common stock for $9.8 million, including rights to 16,915 shares of our common stock to satisfy personal tax liabilities of participants in our stock-based compensation plan for an aggregate purchase price of $211 thousand.

We utilize the non-GAAP financial measure of free cash flow to evaluate our cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures. Management believes that free cash flow provides useful information to investors regarding the cash available in the period that was in excess of our needs to fund our capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income (loss) or cash flows from operating, investing or financing activities, each as determined in accordance with GAAP. Free cash flow does not represent residual cash available for distribution because we may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented, may not be comparable to similarly titled measures presented by other companies. The following table reconciles this non-GAAP financial measure to the most directly comparable measure calculated and presented in accordance with GAAP (in thousands):

33

Return to Index

		Nine Months Ended September 30,
		2025				2024				% Change
Free cash flow calculation:
Net cash provided by operating activities		$	29,085			$	35,773			(19)%
Less: Cash paid for capital expenditures - operations			(8,265	)			(8,647	)		(4)%
Free cash flow		$	20,820			$	27,126			(23)%

Free cash flow for the nine months ended September 30, 2025, decreased $6.3 million from $27.1 million for the same period in 2024. The net cash provided by operating activities of $29.1 million during the nine months ended September 30, 2025, decreased $6.7 million primarily due to the factors as discussed in the cash flow from operating activities above. Capital expenditures-operations, which exclude capital expenditures of $2.7 million associated with the Aberdeen, U.K. fire incident and are covered by insurance, decreased slightly by $0.4 million during the nine months ended September 30, 2025 compared to the same period in the prior year.

Credit Facility, Senior Notes and Available Future Liquidity

We, along with CLIH, have a secured the Credit Facility for an aggregate borrowing commitment of $150.0 million with a $50.0 million “accordion” feature. As of September 30, 2025, the Credit Facility has an available borrowing capacity of approximately $131.9 million.

See Note 7 – Long-term debt, net of the Notes to the Interim Consolidated Financial Statements, for additional information regarding the Credit Facility.

Additionally, we along with CLIH as issuer, have senior notes outstanding that were issued through private placement transactions.

These debt instruments are summarized in the following table (in thousands):

	Interest Rate		Maturity Date		September 30, 2025				December 31, 2024
Credit Facility					$	7,000			$	18,000
2021 Senior Notes Series A (1)	4.09%		January 12, 2026			45,000				45,000
2021 Senior Notes Series B (1)	4.38%		January 12, 2028			15,000				15,000
2023 Senior Notes Series A (2)	7.25%		June 28, 2028			25,000				25,000
2023 Senior Notes Series B (2)	7.50%		June 28, 2030			25,000				25,000
Total long-term debt						117,000				128,000
Less: Debt issuance costs						(2,897	)			(1,889	)
Long-term debt, net					$	114,103			$	126,111

(1) Interest is payable semi-annually on June 30 and December 30.

(2) Interest is payable semi-annually on March 28 and September 28.

In accordance with the terms of the Credit Facility, our leverage ratio is 1.10, and our interest coverage ratio is 7.86, each for the period ended September 30, 2025. We are in compliance with all covenants contained in our Credit Facility and Senior Notes as of September 30, 2025. Certain of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes. See Note 7 - Long-term Debt, net of the Notes to the Interim Consolidated Financial Statements for additional information regarding the terms and financial covenants of the Credit Facility and the Senior Notes.

See Note 11 - Derivative Instruments and Hedging Activities of the Notes to the Interim Consolidated Financial Statements, for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our Credit Facility and the 2023 Senior Notes.

34

Return to Index

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in market risk from the information provided in Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” of Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024.

Item 4. Controls and Procedures

A complete discussion of our controls and procedures is included in Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024.

Disclosure Controls and Procedures

Our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2025, at the reasonable assurance level.

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. Further, the design of disclosure controls and internal control over financial reporting must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There have been no changes in our system of internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the fiscal quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

CORE LABORATORIES INC.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

See Note 9 - Commitments and Contingencies of the Notes to the Interim Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report.

Item 1A. Risk Factors

Our business faces many risks. Any of the risks discussed in this Quarterly Report or our other SEC filings could have a material impact on our business, financial position or results of operations.

Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also impair our business operations. For a detailed discussion of the risk factors that should be understood by any investor contemplating investment in our securities, please refer to “Item 1A - Risk Factors” in Core Laboratories Inc.’s Annual Report on Form 10-K

35

Return to Index

for the year ended December 31, 2024. In addition to the risk factors identified in our 2024 Annual Report, we updated the following risk factor:

Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flows.

Our business and results of operations may be adversely affected by uncertainty and changes in U.S. trade policies, including tariffs, trade agreements or other trade restrictions imposed by the U.S. or other governments. Our input costs for raw materials and other goods, such as steel, electronic components, chemical reagents and laboratory equipment, are adversely affected by tariffs imposed by the U.S. government on products imported into the United States. Additionally, we sell our products internationally and our product sales may be subject to any retaliatory measures by other countries. Any imposition of or increase in tariffs on the goods we purchase or the products we sell could increase our costs and the price of our products and services. To the extent we are unable to pass all or a portion of these cost increases on to our customers, such cost increases could adversely affect our results of operations.

Additional tariffs, further trade restrictions and retaliatory trade measures could disrupt our supply chain and logistics, restrict or limit the availability of goods or supplies, cause adverse financial impacts due to volatility in foreign exchange rates and interest rates, and inflationary pressures on raw materials. It may be time-consuming and expensive for us to alter our business operations to adapt to or comply with any changes in international trade policies and agreements and any failure to do so could have a material adverse effect on our business. Any potential impact will depend on future developments with respect to trade policy and the results of trade negotiations, all of which are beyond our control. These potential impacts, while uncertain, could adversely affect our business, results of operations and financial condition.

Tariffs or other trade restrictions may lead to continuing uncertainty and volatility in U.S. and global financial and economic conditions and commodity markets, declining consumer confidence, significant inflation and diminished expectations for the economy, and ultimately reduced demand for our products and services and the demand for crude oil and gas. Such conditions could have a material adverse impact on our business, results of operations and cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Issuer Purchases of Equity Securities

The following table provides information about our purchases of shares of our common stock, par value $0.01, that are registered by us pursuant to Section 12 of the Exchange Act during the three months ended September 30, 2025:

Period		Total Number of Shares Purchased (1)				Average Price Paid Per Share				Total Number of Shares Purchased as Part of a Publicly Announced Program (2)				Maximum Number of Shares That May Yet be Purchased Under the Program (2)
July 1-31, 2025			172,070			$	11.45				—				—
August 1-31, 2025			275,030			$	10.38				—				—
September 1-30, 2025			15,148			$	12.16				—				—
Total			462,248			$	10.84				—

(1)During the three months ended September 30, 2025, 4,461 shares were surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award. Additionally, we purchased 457,787 shares in the open market. Repurchases of common stock are at the discretion of the board of directors and management.

36

Return to Index

(2)The Company does not have a formal share repurchase program; however, it does from time to time undertake share repurchases in the open market at the discretion of Company management and with prior authorization from the Board of Directors.

Item 5. Other Information

During the three months ended September 30, 2025, no director or officer of the Company adopted, modified or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” within the meaning of Item 408(a) of Item 408 of Regulation S-K.

37

Return to Index

Item 6. Exhibits

Exhibit No.		Exhibit Title		Incorporated by reference from the following documents
10.1	-	Core Laboratories Inc. Nonqualified Deferred Compensation Plan for Board of Directors		Filed herewith
10.2	-	Ninth Amended and Restated Credit Agreement, dated July 22, 2025, by and among, Core Laboratories Inc. and Core Laboratories (U.S.) Interests Holdings, Inc., as borrowers, Bank of America, N.A., as administrative agent and the other lenders party hereto		Form 8-K, July 23, 2025 (File No. 001-41695)
31.1	-	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002		Filed herewith
31.2	-	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002		Filed herewith
32.1	-	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002		Furnished herewith
32.2	-	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002		Furnished herewith
101.INS	-	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document		Filed herewith
101.SCH	-	Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents		Filed herewith
104	-	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)		Filed herewith

38

Return to Index

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, Core Laboratories Inc., has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CORE LABORATORIES INC.
Date:	October 23, 2025	By:	/s/ Christopher S. Hill
			Christopher S. Hill
			Chief Financial Officer
			(Duly Authorized Officer and
			Principal Financial Officer)

39

Return to Index

FAQ

How did Core Laboratories (CLB) perform in Q3 2025?

Revenue was $134.5 million, flat year over year. Net income attributable to the company was $14.2 million and diluted EPS was $0.30.

What drove CLB’s segment results in Q3 2025?

Services rose to $101.1 million on international crude‑assay and diagnostics. Product sales declined to $33.4 million on softer U.S. onshore completions.

Did non-operating items affect Q3 2025 results for CLB?

Yes. The company recorded a final insurance recovery gain of about $5.2 million related to the Aberdeen facility.

What is CLB’s debt and liquidity position?

Gross long‑term debt was $117.0 million. Under the amended $150.0 million credit facility, available borrowing capacity was about $131.9 million at quarter‑end.

Did CLB return capital to shareholders?

The board declared a $0.01 quarterly dividend on Oct 22, 2025. Year to date, the company repurchased 831,478 shares for $9.8 million.

What acquisitions did CLB make after Q3 2025?

On Oct 1, 2025, CLB acquired Solintec in Brazil for an initial $2.3 million plus up to $3.7 million contingent consideration.

How did taxes and interest expense trend in Q3 2025?

Income tax expense was $3.8 million (effective rate 20.5%), and interest expense declined to $2.7 million.